Alzheimer’s Drugs Market Analysis And Forecast - Pfizer, Janssen Pharmaceutical, Novartis International AG, Eisai

The Global Alzheimer’s Drugs Market, by Drug (Donepezil, Rivastigmine, Galantamine and Memantine) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 7 billion in 2016 and is projected to exhibit a CAGR of 9.5% over the forecast period (2017 – 2025), as highlighted in a new report published by Coherent Market Insights. The Alzheimer’s drugs market is expected to gain significant traction with the increasing innovations in development of novel drugs by the manufacturers and increased government funding for research on Alzheimer’s pathophysiology to develop treatment and diagnosis of Alzheimer’s disease.

Request For Sample Copy of This Research Report: www.coherentmarketinsights.com/insight/request-sample/1373

Increasing aging population, improved diagnostics and development of novel drugs to drive growth of the Alzheimer’s drugs market

Increasing age is highest risk factor for Alzheimer’s disease, which is expected to propel demand for Alzheimer’s therapeutics. This is on account of increased life expectancy in global population, for instance according World Population Prospect report 2017, there is significant gains in life expectancy achieved globally in past decade, life expectancy at birth rose from approximately 67 to 71 years and all regions shared in the rise of life expectancy and in next several decades it would rise up to 78 years on average. As Alzheimer’s is most prevalent in age 65 year and above therefore increased life expectancy would face more patients with mild to moderate Alzheimer’s symptoms such as dementia. Europe currently has largest aged population above 60 years.

Key Takeaways of the Alzheimer’s Drugs Market:

The global Alzheimer’s drugs market is expected to exhibit a CAGR of 9.5% over the forecast period, owing to the presence of high potential market on account of aging population with increased life expectancy and rising awareness about disease in North America, Europe, and Asia Pacific.
Among different regions, North America holds largest share in Alzheimer’s drugs market, owing to high prevalence of Alzheimer’s disease and easy diagnosis and treatment access in region
Key players operating in Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S, and Teva Pharmaceuticals Industries Ltd

People suffering from early stage of Alzheimer’s disease with some dementia do not have appropriate access to the healthcare infrastructure to diagnose and treat the disease. For instance according to World Alzheimer Report in 2016, only around 50% patients suffering from dementia undergo diagnosis. The rate of underdiagnoses is 10% in low and middle income economies, therefore, this is expected to propel growth of Alzheimer’s drugs market. As of 2011, there were no standard guidelines for diagnosis of disease. Currently, biomarker tests involving amount of beta-amyloid in the brain, which can be visualized in positron emission tomography imaging are under research to diagnosis develop treatment for Alzheimer’s disease. Currently, there is no curative therapy available for Alzheimer’s disease. However, drugs for Alzheimer’s therapy are in pipeline, which are expected to launch in near future, which in turn is propelling growth of Alzheimer’s disease therapeutics market.

Key players operating in Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other prominent players whose products are under clinical trials are Eli Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.

Download The PDF Brochure: www.coherentmarketinsights.com/insight/request-pdf/1373

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.